US EditionRSV Antibody Treatment Effective For Babies
- Researchers led by Seyed Moghadas reported on May 1 that the antibody treatment nirsevimab reduces respiratory syncytial virus risks in infants during the 2023-2024 season across five countries.
- Researchers analyzed combined data from 27 studies involving 36,949 infants born to mothers in several European countries and the United States, finding that the treatment’s effectiveness against RSV differed depending on the country.
- Nirsevimab decreased the likelihood of hospitalization by 83%, intensive care unit admissions by 81%, and cases of respiratory infections affecting the lower airways by 75% in infants under one year old, offering greater protection for those older than three months.
- In the U.S., 93% of treated infants avoided hospitalization despite limited antibody supply and prioritization of high-risk babies, while racial disparities showed lower immunization rates for some groups.
- These results demonstrate that nirsevimab effectively lowers RSV impact and related healthcare demands, emphasizing the value of protecting newborns through both early-life antibody treatments and maternal vaccination strategies.
35 Articles
35 Articles
Most Babies Protected Against RSV During First Season Immunization Was Available
(MedPage Today) -- During the first respiratory syncytial virus (RSV) season in which a maternal vaccine and a monoclonal antibody for infants were available, most infants were immunized via either intervention, according to an analysis of Vaccine...
Daily Journal
RSV Antibody Treatment Effective For Babies
Key Takeaways
Breastfeeding is the only food that provides the nutrients necessary to grow and fully develop the baby’s immune system. In times of increased circulation of respiratory viruses, it is essential to sustain it to strengthen defenses and prevent diseases. In autumn and winter, one of the most prevalent viruses in children under two years of age is the Respiratory Syncicial Virus (RSV), which causes diseases such as bronchiolitis and pneumonia, whi…
In the context that Vietnam does not have a vaccine to prevent respiratory syncytial virus (RSV), injecting the monoclonal antibody Palivizumab is an effective solution.
Coverage Details
Bias Distribution
- 38% of the sources lean Left, 38% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
